托西利祖马布,沙利卢马布和阿纳金拉在COVID-19的重症患者中:一个随机,受控,开放标签,适应性平台试验
Lennie Derde1, Anthony C Gordon2, Paul R Mouncey3
1Intensive Care Center, University Medical Centre, Utrecht, Netherlands.
Thorax
|May 13, 2025
概括
托西利祖马布和沙利祖马布对重症COVID-19患者提供了同等的好处,改善了器官支持持续时间和生存率. 阿纳金拉在这个患者群体中没有显著的有效性.
科学领域:
- 关键护理医学 关键护理医学
- 免疫学 免疫学 免疫学
- 传染病 传染病 传染病
背景情况:
- 托西利祖马布在改善重症COVID-19患者的治疗结果方面已经证明有效.
- 其他免疫调节策略的比较有效性仍然不确定.
研究的目的:
- 为了评估托西利祖马布,沙利祖马布和阿纳金拉的疗效,与在严重病情的COVID-19患者中没有免疫调节相比.
- 为了确定替代性免疫调节治疗是否提供优越或同等效益.
主要方法:
- 一个适应性平台试验,涉及9个国家的133个站点.
- 随机分配重症COVID-19患者到托西利祖马布,沙利祖马布,阿纳金拉或对照组.
- 主要结局用顺序尺度测量,结合住院死亡率和21天内无器官支持的日子.
主要成果:
- 与对照组相比,托西利祖马布和沙利祖马布的疗效更高,具有很高的优势概率 (两者均为99.8%).
- 阿纳金拉在对照组中没有显著的益处 (46.6%的优势概率).
- 中位数无器官支持日为托西利祖马布7天,沙利祖马布9天,相比之下,阿纳金拉和对照组0天.
结论:
- 托西利祖马布和沙利祖马布在降低重症COVID-19患者的死亡率和器官支持的持续时间方面同样有效.
- 阿纳金拉对这种患者群体没有效果.
- 托西利祖马布和沙利祖马布都被发现是安全的.
更多相关视频
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
500
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103
Tumor Immunotherapy
411
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
411
